Back

Design and rationale for MAGNITUDE, a phase 3, randomised, placebo-controlled trial of NTLA-2001, a CRISPR-based gene editing therapy, in patients with transthyretin amyloidosis with cardiomyopathy

11 May 2024 (08:00 - 20:00)
Organised by: Logo
Congress Presentation Part of: Myocardial disease - clinical 5 Clinical HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Mathew Maurer

Columbia University Irving Medical Centre, New York (United States of America)

7 More presentations in this session

Presentation thumbnail
T-Amylo score for the diagnosis of transthyretin cardiac amyloidosis in patients with acute heart failure.
Ms M. Diez (Buenos Aires, AR)
Abstract Slides Video
Presentation thumbnail
Prevalence, clinical significance and prognosis value of liver stiffness measurement anomalies in transthyretin cardiac amyloidosis
Mrs E. Lointier (Toulouse, FR)
Abstract Slides Video
Presentation thumbnail
Right ventricular to pulmonary artery uncoupling is an early predictor of poor outcome in wild-type transthyretin cardiac amyloidosis
Doctor G. Sinigiani (Padua, IT)
Abstract Slides Video
Presentation thumbnail
Impairment of right ventricular to pulmonary artery coupling is associated with worse survival in cardiac amyloidosis
Doctor A. Jakstaite (Hannover, DE)
Abstract Slides Video
Presentation thumbnail
Utility of KAsH score in predicting in-hospital mortality in takotsubo cardiomyopathy
Doctor I. Martins Moreira (Vila Real, PT)
Abstract Slides Video

Access the full session

Session thumbnail
Myocardial disease - clinical 5

The Event

Event poster

Heart Failure 2024

11 May - 14 May 2024
You may be interested in
thumbnail
Congress Presentation
Discussant review - CRISPR gene editing with nexiguran ziclumeran in ATTR cardiomyopathy: treatment effect in hereditary vs. wild-type disease
thumbnail
Congress Presentation
CRISPR gene editing with nexiguran ziclumeran in ATTR cardiomyopathy: treatment effect in hereditary vs. wild-type disease
thumbnail
Congress Presentation
Design and rationale of a phase 3 study to evaluate the efficacy and safety of nucresiran (ALN-TTRsc04) in patients with transthyretin amyloidosis with cardiomyopathy

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources